SCHEMBL312000

SCHEMBL312000

O=c1cc(-c2ccc(O)cc2)[nH]c2ccc(O)cc12

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 10/20 0.61
KDM4E B2RXH2 9/20 0.61
ALDH1A1 P00352 8/20 0.61
RAB9A P51151 7/20 0.61
NPC1 O15118 6/20 0.61
SMN1; SMN2 Q16637 6/20 0.61
LMNA P02545 5/20 0.61
KMT2A Q03164 5/20 0.61
MEN1 O00255 4/20 0.61
MAPK1 P28482 1/20 0.61
PDE10A Q9Y233 2/20 0.55
TP53 P04637 2/20 0.54
HSD17B10 Q99714 2/20 0.54
MAPT P10636 1/20 0.54
CTSV O60911 3/20 0.53
CTSL P07711 3/20 0.53
TUBB4A P04350 1/20 0.53
TUBB P07437 1/20 0.53
TUBA3C P0DPH7 1/20 0.53
TUBA1B P68363 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9385766 0.90 HPGD (0.68) HPGDKDM4EALDH1A1RAB9ANPC1
SCHEMBL312265 0.87 SMN1; SMN2 (0.74) HPGDKDM4EALDH1A1RAB9ANPC1
SCHEMBL312386 0.86 KDM4E (0.55) HPGDKDM4EALDH1A1RAB9ANPC1
SCHEMBL311524 0.85 CTSV (0.75) HPGDKDM4EALDH1A1RAB9ANPC1
SCHEMBL311852 0.85 KDM4E (0.51) HPGDKDM4EALDH1A1RAB9ANPC1
SCHEMBL31552890 0.85 KDM4E (0.51) HPGDKDM4EALDH1A1RAB9ANPC1
SCHEMBL339089 0.84 RAB9A (0.55) HPGDKDM4EALDH1A1RAB9ANPC1
SCHEMBL25910968 0.84 KDM4E (0.55) HPGDKDM4EALDH1A1RAB9ANPC1
SCHEMBL312025 0.82 KDM4E (0.51) HPGDKDM4EALDH1A1RAB9ANPC1
SCHEMBL340109 0.80 TUBB4A (0.61) HPGDKDM4EALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 US disclosed
EP-1838296-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2007-10-03 EP disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed
WO-2006045096-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 HPGD 138/4885KDM4E 3504/4885ALDH1A1 1211/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 HPGD 138/4885KDM4E 3504/4885ALDH1A1 1211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.